SML3907
CNS-11g
≥98% (HPLC)
Synonym(s):
2-(4-benzyl-1-oxo-2(1H)-phthalazinyl)-N-(2,6-dimethylphenyl)acetamide, N-(2,6-Dimethylphenyl)-1-oxo-4-(phenylmethyl)-2(1H)-phthalazineacetamide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
2-8°C
Biochem/physiol Actions
Brain tissue penetrant alpha-synuclein ligand that potently disaggregate alpha-synuclein fibrils in vitro and in vivo models.
CNS-11g is brain tissue penetrant alpha-synuclein ligand that potently disaggregate alpha-synuclein fibrils in vitro and in vivo models. CNS-11g inhibits intracellular seeding of a-synuclein fibrils in biosensor cells-HEK293T cells and mitigate a-synuclein cytotoxicity in Neuro-2a (N2a) neuronal cells. C-11g reduces number of a-synuclein aggregates in C. elegans model.
CNS-11g is brain tissue penetrant alpha-synuclein ligand that potently disaggregate alpha-synuclein fibrils in vitro and in vivo models. CNS-11g inhibits intracellular seeding of a-synuclein fibrils in biosensor cells-HEK293T cells and mitigate a-synuclein cytotoxicity in Neuro-2a (N2a) neuronal cells. C-11g reduces number of a-synuclein aggregates in C. elegans model.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils.
Proceedings of the National Academy of Sciences of the United States of America, 120(7), e2217835120-e2217835120 (2023-02-10)
The amyloid aggregation of alpha-synuclein within the brain is associated with the pathogenesis of Parkinson's disease (PD) and other related synucleinopathies, including multiple system atrophy (MSA). Alpha-synuclein aggregates are a major therapeutic target for treatment of these diseases. We identify
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service